Review explores medical cannabis and CBD potential for Malawi, including possible neuroprotective role in malaria
A review of CBD science following Malawi's 2020 cannabis legalization highlights its established use in epilepsy and emerging evidence for neuroprotection, including a novel proposal for malaria-related brain injury.
Quick Facts
What This Study Found
CBD has an established role in treating epilepsy (FDA-approved Epidiolex) and emerging evidence for antipsychotic and neuroprotective properties, with the authors proposing potential adjunctive use for neuropsychological complications of malaria.
Key Numbers
Malawi legalized medical cannabis in February 2020; Epidiolex was the first FDA-approved cannabis-based treatment.
How They Did This
Special communication reviewing published literature on cannabis pharmacology, CBD mechanisms of action, FDA-approved treatments, and clinical research on CBD's antipsychotic and neuroprotective properties.
Why This Research Matters
As Malawi joins the growing list of countries legalizing medical cannabis, this review frames the scientific evidence for CBD in a context relevant to local public health challenges, particularly malaria.
The Bigger Picture
The intersection of cannabis legalization in African nations with local disease burdens like malaria opens new research questions about whether cannabinoids could address region-specific health challenges.
What This Study Doesn't Tell Us
The proposal for CBD in malaria-related neuroprotection is speculative and lacks clinical evidence. The review is broad rather than systematic. Limited discussion of local implementation challenges.
Questions This Raises
- ?Could CBD actually provide neuroprotection in complicated malaria cases?
- ?What infrastructure does Malawi need to develop evidence-based medical cannabis programs?
Trust & Context
- Key Stat:
- First FDA-approved cannabis medicine: Epidiolex for epilepsy
- Evidence Grade:
- Broad review with established evidence for epilepsy but speculative proposals for other conditions.
- Study Age:
- Published in 2022, contextualizing Malawi's 2020 cannabis legalization.
- Original Title:
- Medical cannabis and cannabidiol: A new harvest for Malawi.
- Published In:
- Malawi medical journal : the journal of Medical Association of Malawi, 34(2), 138-142 (2022)
- Authors:
- Bandawe, Gama
- Database ID:
- RTHC-03690
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is CBD's most established medical use?
CBD is FDA-approved as Epidiolex for treating certain forms of epilepsy, making it the most evidence-backed medical use of a cannabis-derived compound.
What novel use does this review propose for CBD?
The authors propose that CBD could serve as a neuroprotective adjunctive therapy for preventing neuropsychological complications associated with complicated malaria, though this remains speculative.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03690APA
Bandawe, Gama. (2022). Medical cannabis and cannabidiol: A new harvest for Malawi.. Malawi medical journal : the journal of Medical Association of Malawi, 34(2), 138-142. https://doi.org/10.4314/mmj.v34i2.10
MLA
Bandawe, Gama. "Medical cannabis and cannabidiol: A new harvest for Malawi.." Malawi medical journal : the journal of Medical Association of Malawi, 2022. https://doi.org/10.4314/mmj.v34i2.10
RethinkTHC
RethinkTHC Research Database. "Medical cannabis and cannabidiol: A new harvest for Malawi." RTHC-03690. Retrieved from https://rethinkthc.com/research/bandawe-2022-medical-cannabis-and-cannabidiol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.